Smart Connected Drug Delivery Devices Market Size & Share 2026-2035

Smart Connected Drug Delivery Devices Market Size

The global smart connected drug delivery devices market was valued USD 603.9 million in 2025 and is projected to grow from USD 700 million in 2026 to USD 5.1 billion in 2035, at a forecast CAGR of 24.6%.

Smart connected drug delivery devices combine delivery hardware with Bluetooth, near-field communication (NFC), Wi-Fi, cellular connectivity, sensors, software, and clinical data interfaces. The category includes connected inhalers, smart pens, insulin pumps, autoinjectors, wearable on-body systems, and retrofittable sensor attachments. Their commercial value lies in converting a dosing event into usable information on timing, technique, completion, and, in some systems, physiological response.

Medication non-adherence creates the central demand condition. In the United States, approximately one in five new prescriptions is not filled, and about half of filled prescriptions are not taken as directed; CDC estimates place annual direct costs associated with non-adherence at USD 100 billion to USD 300 billion ^{[1]Centers for Disease Control and Prevention - Improving Medication Adherence for Chronic Disease Management, November 2017 - cdc.gov}. Cost-related non-adherence among adults with diabetes, cardiovascular disease, or hypertension is also associated with higher all-cause mortality ^{[2]Centers for Disease Control and Prevention - Cost-Related Nonadherence and Mortality, 2020 - cdc.gov}. Connected devices do not resolve affordability or treatment complexity on their own, but they can create an auditable record that helps clinicians distinguish missed doses, poor administration technique, and insufficient therapeutic response.

The addressable disease base is broad. The World Health Organization identifies chronic respiratory disease as a major global health burden, while COPD caused 3.4 million deaths in 2023 ^{[3]World Health Organization - Chronic Obstructive Pulmonary Disease (COPD), November 2024 - who.int}. The International Diabetes Federation estimates that 589 million adults aged 20–79 were living with diabetes in 2024 and projects this population to reach 853 million by 2050 ^{[4]International Diabetes Federation - IDF Diabetes Atlas, 11th Edition, 2025 - ncbi.nlm.nih.gov}. These conditions favor recurring, self-administered therapies, making adherence and dosing visibility commercially relevant to device makers, pharmaceutical sponsors, providers, and payers.

Growth is being shaped by the interaction of chronic-care delivery, remote monitoring, and combination-product development. Platform suppliers increasingly offer modular connectivity features that pharmaceutical sponsors can apply to existing delivery formats. Ypsomed's FDA-cleared SmartPilot add-on, for example, creates a connectivity layer for the YpsoMate autoinjector platform rather than requiring a drug sponsor to develop an entirely new connected delivery device. In Europe, the Medical Device Regulation framework strengthens post-market surveillance and device-identification obligations, increasing the value of reliable data capture and lifecycle-management capabilities.

Two commercial models are emerging. Retrofittable sensors and NFC-enabled accessories address broad populations using established inhalers and pens, where the immediate value is dose confirmation or technique monitoring. Integrated pumps, electromechanical injectors, and wearable systems address higher-acuity or high-value therapies, where connectivity can support algorithmic dosing, care coordination, and real-world evidence generation. The latter model carries greater development and cybersecurity requirements, but it also offers a deeper role in the treatment pathway.

Key Drivers

Patient awareness and the adherence imperative

Connected delivery systems address a practical limitation of conventional devices: clinicians often know that treatment has failed but cannot determine whether the cause was missed medication, incorrect technique, insufficient dose, or poor response to the drug. That distinction is especially relevant in respiratory care, where an inhaler actuation may not correspond to effective inhalation. An evaluation of Aptar Digital Health's respiratory platform reported reduced rescue-medication use and improved asthma-control outcomes over a 90-day period, illustrating how technique and adherence data can become part of clinical intervention rather than a passive patient reminder.

For diabetes, the value proposition extends from adherence logging to closed-loop delivery. Insulet's Omnipod 5 integrates automated insulin delivery with continuous glucose-monitoring data, and its U.S. indication expansion for type 2 diabetes broadened the system's potential patient base ^{[5]Insulet Corporation - Annual Report 2024, February 2025 - sec.gov}. The commercial significance is not simply that the device is connected; it is that dosing data can be linked to glucose data and interpreted through an established clinical-management framework.

Healthcare IT infrastructure and remote monitoring

Healthcare organizations are directing more capital toward digital and IT systems. A Healthcare Financial Management Association survey reported that more than 85% of health systems were increasing digital and IT budgets, while surveyed organizations reported average digital and IT budget growth of 18.3% between 2019 and 2023 ^{[6]Healthcare IT News - Providers Report Significant IT Budget Increases in 2024, 2024 - healthcareitnews.com}. Investment alone does not guarantee connected-device adoption. Its importance lies in enabling the interfaces, cloud governance, electronic health record integration, and clinical-monitoring teams required to make device data actionable.

Connected respiratory platforms demonstrate this infrastructure dependency. Adherium states that its Hailie platform integrates with Epic and Oracle Health/Cerner workflows, creating a path from inhaler-use data to clinical documentation ^{[7]Adherium - Annual Report 2024, 2024 - adherium.com}. For device suppliers, interoperability is therefore becoming a procurement requirement rather than an optional software feature. A device that produces adherence data but cannot be incorporated into population-health or specialty-care workflows risks remaining a niche accessory.

AI-enabled delivery and digital decision support

Artificial intelligence is most commercially relevant when it improves a defined dosing or intervention decision. FDA finalized guidance on Predetermined Change Control Plans for AI-enabled device software functions in December 2024, establishing a framework through which sponsors can plan specified modifications to algorithms after authorization ^{[8]U.S. Government Publishing Office - Marketing Submission Recommendations for a Predetermined Change Control Plan for AI-Enabled Device Software Functions, December 2024 - govinfo.gov}. The agency also issued draft lifecycle-management guidance for AI-enabled device software functions in January 2025 ^{[9]U.S. Government Publishing Office - AI-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations, January 2025 - govinfo.gov}. These measures do not eliminate the validation burden of adaptive software, but they clarify how developers can address controlled algorithm change.

In diabetes, automated insulin-delivery platforms represent the most mature illustration of this model. Medtronic's MiniMed 780G uses SmartGuard technology and connected glucose data to support automated insulin management, while its diabetes business reported fiscal 2024 revenue growth supported by demand for the system. Beyond dosing automation, reinforcement-learning approaches have shown potential to tailor medication-support communications for people with type 2 diabetes, indicating that future value may also arise from intervention timing rather than delivery hardware alone.

Telehealth and home-based care

Telehealth makes connected delivery data more useful because it creates a recurring pathway for care teams to review and act on the information without requiring an in-person visit. Smart pen and continuous glucose-monitoring data have been used in telemedicine care for type 1 diabetes, supporting treatment adjustment in patients whose glycemic control had not improved under conventional management.

Home care settings generated USD 244.5 million in market revenue in 2025. This leadership reflects the shift toward self-administration of insulin, respiratory therapies, and biologics outside hospitals. BD's Libertas wearable injector entered a first pharmaceutical-sponsored combination-product clinical trial in July 2025, demonstrating continued development of large-volume subcutaneous delivery systems intended for home or ambulatory use. Enable Injections' enFuse system has also secured regulatory milestones across multiple markets for large-volume subcutaneous delivery, supporting the transition of selected biologic therapies from supervised infusion settings to self-administration models.

Key Restraints

A connected delivery device can transmit dosing behavior, therapy history, and, depending on the platform, associated physiological information. That architecture broadens the product's risk profile beyond mechanical delivery performance. The U.S. Government Accountability Office has documented that medical-device cybersecurity vulnerabilities can contribute to adverse events and recalls. For connected devices, cybersecurity weaknesses can affect patient trust, provider adoption, and the commercial viability of a software ecosystem.

Section 524B of the Federal Food, Drug, and Cosmetic Act requires manufacturers of cyber devices to provide cybersecurity information in relevant premarket submissions. FDA subsequently updated its recommendations for changes to previously authorized cyber devices in 2025. These requirements favor companies able to maintain secure software-development, vulnerability-management, and post-market processes. They can be particularly demanding for smaller companies trying to commercialize hardware, software, cloud services, and clinical interfaces simultaneously.

European requirements add a separate layer of governance. The EU Medical Device Regulation governs device safety and post-market obligations, while the EU AI Act introduces risk-based obligations relevant to certain AI-enabled medical applications,. Compliance can improve market confidence, but it increases the importance of regulatory design choices early in device development.

High device price and uneven reimbursement

Connected systems carry costs that conventional devices often do not: sensors, wireless modules, batteries, software maintenance, cybersecurity controls, cloud infrastructure, validation, and customer support. The premium is especially pronounced for electromechanical autoinjectors, on-body systems, and integrated insulin-delivery platforms. In settings where reimbursement does not recognize the clinical value of adherence or remote therapeutic data, those costs are difficult to recover.

The constraint differs by technology. NFC can support lower-cost, episodic data transfer for pen-based therapy, while Bluetooth and Wi-Fi systems can support richer and more continuous data exchange but require broader hardware and software infrastructure. This makes product-tiering a likely route to market expansion. Lower-cost accessories may establish adoption in price-sensitive settings, whereas fully integrated devices are more likely to gain traction first in reimbursed chronic-care programs and therapies with high drug value.

The same conditions create a barrier to broad commoditization. Device makers must carry the cost of cybersecurity, data governance, interoperability, and regulatory maintenance before scale is achieved. As a result, established platforms with regulatory experience and pharmaceutical relationships are likely to retain an advantage in high-value delivery categories, while lower-cost sensor and NFC models may be more suitable for widening access in markets where reimbursement is incomplete.

Smart Connected Drug Delivery Devices Market Segment Analysis

By Product

Integrated devices held 60.8% of market revenue in 2025. These systems embed connectivity directly within the delivery platform, enabling the device to capture events such as injection completion, pump operation, inhaler actuation, or dose history without relying solely on an external attachment. Their principal advantage is data fidelity: the system can capture the delivery action at its source and connect it to device-specific safety checks, algorithmic logic, or companion software.

Integrated injectable systems account for much of this position. Insulet's Omnipod 5 and Medtronic's MiniMed platform combine delivery mechanics, software, and continuous glucose-monitoring interfaces in a single therapeutic system. At the other end of the injectable spectrum, reusable electromechanical autoinjectors are being designed for high-value biologics. SHL Medical's Elexy platform incorporates reusable electromechanical delivery, drug-cassette identification, and connectivity capabilities, targeting therapies where confirmation of use and differentiation of the delivery experience are commercially important.

Connected sensors generated USD 236.5 million in 2025 and are forecast to expand at a 24.7% CAGR through 2035. Their appeal is modularity. A sensor or cap can add connectivity to a conventional inhaler or pen without forcing a pharmaceutical sponsor to redesign the primary delivery system. Adherium's portfolio includes FDA-cleared sensors for multiple inhaler products, while Aptar Digital Health received FDA clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers. In injectable therapy, Biocorp's SoloSmart clearance illustrates the application of connected caps to disposable insulin and GLP-1 pen formats.

By Technology

Bluetooth held 47.6% of market revenue in 2025. It is well suited to platforms that require regular data transfer among a delivery device, smartphone, continuous glucose monitor, and cloud application. The installed base of Bluetooth-enabled smartphones lowers adoption friction, but it also makes companion-app reliability and data-security design central to the user experience. Diabetes platforms have led this model because treatment decisions benefit from frequent interaction between dosing and glucose data.

NFC generated USD 174.7 million in 2025 and is forecast to grow at a 24.6% CAGR. It supports a different operating model: the user taps the pen or accessory against a compatible device to transfer stored dose information. Novo Nordisk's NovoPen 6 and NovoPen Echo Plus use NFC to transfer dosing information, making the technology appropriate for therapies where periodic dose logging is sufficient and continuous transmission would add cost without equivalent clinical value.

Wi-Fi generated USD 141.5 million in 2025 and is forecast to grow at a 24.9% CAGR. Its relevance is greatest where direct access to home or institutional networks can reduce reliance on manual smartphone synchronization. Wi-Fi and cellular connectivity may be particularly useful for home-based biologic delivery, hospital-linked systems, and programs where the sponsor requires timely confirmation that a dose was completed. Connectivity choice will remain application-specific; no single protocol is likely to dominate every therapeutic use case.

By Application

Respiratory applications generated USD 260.3 million in 2025, making them the largest application segment. The segment benefits from frequent dosing, technique-sensitive administration, and a large chronic-disease population. Connected inhalers can help distinguish an omitted dose from a poorly executed inhalation, an operational distinction that is difficult to establish from prescription-fill data alone. Global chronic respiratory disease burden remains substantial, with the Institute for Health Metrics and Evaluation reporting 569.2 million chronic respiratory disease cases worldwide in 2023.

Diabetes is forecast to expand at a 25.1% CAGR through 2035. Its growth rests on the convergence of smart pens, pumps, continuous glucose monitors, and automated insulin-delivery algorithms. The category is structurally attractive because the clinical feedback loop is measurable: insulin delivery, glucose response, and user behavior can be linked in near real time. The expansion of connected delivery into type 2 diabetes broadens that opportunity beyond the historically concentrated type 1 pump population.

Anaphylaxis, cardiovascular, hormone replacement, oncology, and other applications expand the market beyond its current diabetes and respiratory base. In anaphylaxis, connected autoinjector concepts can support expiry monitoring and documentation of emergency administration, and the segment is anticipated to grow at a 24.5% CAGR from 2026 to 2035. The cardiovascular segment is anticipated to grow at a 24.9% CAGR from 2026 to 2035. In cardiovascular and oncology care, the commercial opportunity is tied to subcutaneous delivery of biologics that have historically required facility-based administration. Enable Injections' partnerships with Serina Therapeutics and Incyte demonstrate how on-body delivery platforms are being evaluated across indications outside diabetes,.

By End Use

Home care settings generated USD 244.5 million in 2025. The setting aligns with the core advantage of connected delivery: it gives patients more autonomy while creating an information trail for clinicians, specialty pharmacies, and support programs. For biologics, the value can include avoiding recurrent infusion-center visits; for diabetes and respiratory care, it can include ongoing remote monitoring of recurring therapy.

Hospitals are forecast to grow at a 24.4% CAGR, and clinics at a 24.6% CAGR. These settings are important not because they represent the primary point of self-administration, but because they establish therapy, troubleshoot technique, and interpret connected-device data for high-risk cohorts. Specialty clinics can also use adherence data to prioritize outreach where a patient's treatment pattern suggests deteriorating control. Other end users include specialty pharmacies and clinical-trial organizations. Gerresheimer's partnership with RxCap illustrates pharmacy-channel use of connected adherence monitoring, while electronic medication monitors have also demonstrated adherence benefits in controlled research settings,.

Integrated systems serve a narrower but more valuable clinical role. In automated insulin delivery and high-value biologic administration, connectivity is part of how the treatment is managed, rather than merely how it is documented. The relative strength of home care confirms that design priorities will increasingly center on onboarding, reliability, accessibility, and low-friction data exchange. Suppliers that treat software support and human factors as core product functions are better positioned than those that approach connectivity as an add-on specification.

Smart Connected Drug Delivery Devices Market Regional Analysis

North America

North America accounted for 43.4% of global market revenue in 2025. The U.S. market increased from USD 162.2 million in 2022 to USD 176.5 million in 2023, USD 197.8 million in 2024, and USD 228.9 million in 2025. It is forecast to grow at a 24.1% CAGR through 2035.

The region's position reflects a combination of chronic-disease prevalence, established digital-health infrastructure, a large pharmaceutical sector, and an active FDA pathway for connected devices and combination products. Recent authorizations include Ypsomed's SmartPilot connectivity add-on, Aptar Digital Health's HeroTracker Sense, and Biocorp's SoloSmart smart cap,. North America also has a relatively developed environment for remote monitoring and specialty-pharmacy programs. Its principal constraint is not the absence of technical capability, but the need to meet cybersecurity, interoperability, and reimbursement expectations across fragmented provider and payer systems.

Europe

Europe generated USD 144.6 million in 2025. Germany, the United Kingdom, France, Spain, Italy, and the Netherlands are relevant markets because their healthcare systems are increasing attention to digital-health integration, chronic-disease management, and home-based care. Germany's digital-health reimbursement environment offers a particularly important test case for software-enabled care models, while the United Kingdom has supported clinical evaluation of connected respiratory management through organizations such as Guy's and St Thomas' NHS Foundation Trust.

The region's regulatory environment is a source of both market discipline and complexity. MDR requirements compel suppliers to maintain clinical, post-market, and device-identification controls, while the EU AI Act raises governance requirements for relevant higher-risk AI applications,. Enable Injections' EU MDR CE Mark milestone for enFuse demonstrates that wearable subcutaneous-delivery platforms are progressing through this compliance environment. European commercial success will depend on whether manufacturers can combine regulatory readiness with country-specific reimbursement and care-pathway strategies.

Asia Pacific

Asia Pacific is projected to record the fastest regional growth, at approximately 25.1% CAGR through 2035. China, Japan, India, Australia, and South Korea present different adoption conditions rather than a single regional market. China combines a large chronic-disease population with extensive digital infrastructure. Japan offers a mature medical-device and reimbursement environment. India has substantial diabetes demand but faces stronger affordability constraints. Australia and South Korea offer conditions in which reimbursement support, diabetes technology adoption, and digital-health partnerships can accelerate use of connected delivery platforms.

The region's opportunity is therefore likely to unfold unevenly. Premium integrated systems may expand first in mature reimbursement markets, while lower-cost pen accessories, inhaler sensors, and pharmaceutical-sponsored programs may provide a more viable route in price-sensitive settings. The most durable regional strategies will need to account for local smartphone access, pharmacy practices, device-registration requirements, and out-of-pocket cost exposure rather than rely on a uniform global launch model.

Latin America

Brazil, Mexico, and Argentina are the principal markets within Latin America. Brazil has established an early foothold for wearable subcutaneous delivery through ANVISA approval of the enFuse system for Empaveli administration. This provides a practical regulatory reference point for connected and digitally supported delivery programs in the region.

Market development remains constrained by reimbursement maturity and device affordability. The near-term opportunity is likely to be concentrated in private care, hospital channels, specialty therapies, and pharmaceutical-sponsored patient-support programs. As digital health infrastructure develops, connected devices may become more relevant to chronic-disease management, but broad access will depend on cost structures that are compatible with local coverage models.

Middle East and Africa

South Africa, Saudi Arabia, and the United Arab Emirates represent the principal regional markets. Saudi Arabia granted authorization for the EMPAVELI Injector based on enFuse technology in December 2025. The Gulf markets can support earlier adoption of premium diabetes and biologic-delivery systems through higher healthcare expenditure and national digital-health programs, while South Africa provides an important private-sector entry point in sub-Saharan Africa.

The region remains comparatively small in current market value because connected delivery systems require dependable device support, data infrastructure, and payment pathways. Pharmaceutical partnerships and specialist-care programs are likely to precede wider retail adoption. Suppliers entering these markets will need to adapt connectivity, service, and data-governance approaches to local clinical and regulatory conditions.

Asia Pacific offers the strongest growth rate because chronic-disease demand and digital infrastructure are expanding together, yet pricing will determine which technologies can scale. Latin America and the Middle East and Africa are more likely to develop through focused pharmaceutical partnerships, specialist channels, and high-value therapies before broad consumer adoption. A single global product configuration is therefore unlikely to optimize performance across regions.

Smart Connected Drug Delivery Devices Market Share & Competitive Landscape

The market is moderately fragmented. Insulet Corporation, Medtronic, Novo Nordisk, Ypsomed, and Tandem Diabetes Care collectively accounted for approximately 45% of market revenue in 2025. Concentration is highest in automated insulin delivery, where software, continuous glucose-monitoring integration, regulatory authorization, and established user support create substantial barriers to entry. Other categories remain more open because pharmaceutical sponsors can select among contract development and manufacturing organizations, platform developers, connectivity specialists, and software partners.

Adherium focuses on connected respiratory monitoring. Its Hailie portfolio includes FDA-cleared inhaler sensors and integrations intended to connect inhaler-use data with clinical workflows.

Aptar Pharma combines pharmaceutical delivery capabilities with Aptar Digital Health software and connected-device programs. HeroTracker Sense and its respiratory disease-management work illustrate Aptar's role in sensor-enabled inhalation and connected therapy services.

Becton, Dickinson and Company is developing wearable-injector platforms for large-volume biologic delivery. BD Libertas is progressing through pharmaceutical-sponsored combination-product development, reflecting BD's focus on converting complex injectable therapies into subcutaneous self-administration formats.

Bayer participates primarily as a pharmaceutical company whose cardiovascular, oncology, and women's-health portfolios can create downstream demand for combination-product and digitally supported delivery platforms. Its competitive relevance is linked to product-specific delivery strategy rather than a stand-alone connected-device platform in the supplied evidence base.

Recent Industry Developments

• September 2025: Ypsomed received FDA 510(k) clearance for SmartPilot, a connectivity add-on for the YpsoMate autoinjector platform.
• September 2025: Gerresheimer expanded its collaboration with Portal Instruments to commercialize the Prime NEXUS reusable connected autoinjector platform.